JP2023541056A5 - - Google Patents

Info

Publication number
JP2023541056A5
JP2023541056A5 JP2023515802A JP2023515802A JP2023541056A5 JP 2023541056 A5 JP2023541056 A5 JP 2023541056A5 JP 2023515802 A JP2023515802 A JP 2023515802A JP 2023515802 A JP2023515802 A JP 2023515802A JP 2023541056 A5 JP2023541056 A5 JP 2023541056A5
Authority
JP
Japan
Prior art keywords
eye
insert according
approximately
delivery insert
eye drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023515802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541056A (ja
JP7848190B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050085 external-priority patent/WO2022056392A1/en
Publication of JP2023541056A publication Critical patent/JP2023541056A/ja
Publication of JP2023541056A5 publication Critical patent/JP2023541056A5/ja
Application granted granted Critical
Publication of JP7848190B2 publication Critical patent/JP7848190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023515802A 2020-09-14 2021-09-13 生体侵食性眼薬送達挿入物及び治療方法 Active JP7848190B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063078265P 2020-09-14 2020-09-14
US63/078,265 2020-09-14
US202163176430P 2021-04-19 2021-04-19
US63/176,430 2021-04-19
US202163190052P 2021-05-18 2021-05-18
US63/190,052 2021-05-18
PCT/US2021/050085 WO2022056392A1 (en) 2020-09-14 2021-09-13 Bioerodible ocular drug delivery insert and therapeutic method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026063649A Division JP2026129731A (ja) 2020-09-14 2026-04-08 生体侵食性眼薬送達挿入物及び治療方法

Publications (3)

Publication Number Publication Date
JP2023541056A JP2023541056A (ja) 2023-09-27
JP2023541056A5 true JP2023541056A5 (enExample) 2024-09-26
JP7848190B2 JP7848190B2 (ja) 2026-04-20

Family

ID=80629914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515802A Active JP7848190B2 (ja) 2020-09-14 2021-09-13 生体侵食性眼薬送達挿入物及び治療方法

Country Status (19)

Country Link
US (3) US12551368B2 (enExample)
EP (2) EP4696325A3 (enExample)
JP (1) JP7848190B2 (enExample)
KR (1) KR20230067641A (enExample)
CN (2) CN115531352B (enExample)
AU (1) AU2021340733A1 (enExample)
BR (1) BR112023004677A2 (enExample)
CA (1) CA3191463A1 (enExample)
DK (1) DK4210682T3 (enExample)
FI (1) FI4210682T3 (enExample)
HR (1) HRP20260727T1 (enExample)
IL (1) IL301227A (enExample)
LT (1) LT4210682T (enExample)
MX (1) MX2023002902A (enExample)
PT (1) PT4210682T (enExample)
RS (1) RS68167B1 (enExample)
SI (1) SI4210682T1 (enExample)
SM (1) SMT202600235T1 (enExample)
WO (1) WO2022056392A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067882A1 (en) 2016-10-05 2018-04-12 Titan Pharmaceuticals, Inc. Implantable devices for drug delivery with reduced burst release
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
IL315331A (en) * 2022-03-11 2024-10-01 Eyepoint Pharmaceuticals Inc A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye
US20250186398A1 (en) * 2022-03-11 2025-06-12 EyePoint Pharmaceuticals, Inc. Continuous dosing regimen for treatment of a condition of the eye
TW202345804A (zh) * 2022-03-11 2023-12-01 美商視點製藥有限公司 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法
US20240024093A1 (en) 2022-07-22 2024-01-25 SpyGlass Pharma, Inc. Intraocular drug delivery systems and methods of use
JP2025525881A (ja) * 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121568687A (zh) 2023-04-27 2026-02-24 艾博莱特克斯有限公司 包含聚乙烯醇的弹性体基质
KR102618788B1 (ko) * 2023-06-19 2023-12-28 국민대학교산학협력단 알티라티닙 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 안질환 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
DK1592407T3 (da) * 2003-01-24 2010-04-19 Psivida Inc Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af carbonanhydraseinhibitorer
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008033562A2 (en) 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-(甲基-氨甲酰基)苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20110238036A1 (en) 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
CA2848397C (en) * 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
WO2013071264A1 (en) 2011-11-11 2013-05-16 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US20160317438A1 (en) 2015-04-29 2016-11-03 Psivida Us, Inc. Injectable sustained release intraocular device
AU2016361579B2 (en) 2015-11-25 2022-08-04 Incept, Llc Shape changing drug delivery devices and methods
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
SG11201901962QA (en) 2016-09-29 2019-04-29 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CA3066437A1 (en) * 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
CN112165923B (zh) * 2018-04-19 2023-07-21 埃弗拉兹疗法有限公司 用于将物质注射到身体组织或器官的夹层中的装置
WO2020177678A1 (zh) * 2019-03-04 2020-09-10 江苏恒瑞医药股份有限公司 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
US20250186398A1 (en) * 2022-03-11 2025-06-12 EyePoint Pharmaceuticals, Inc. Continuous dosing regimen for treatment of a condition of the eye

Similar Documents

Publication Publication Date Title
JP6946503B2 (ja) 眼房内ビマトプロスト注入物による眼圧低下
JP6700348B2 (ja) 持続型薬物送達インプラント
CN115531352B (zh) 可生物蚀解的眼部药物递送插入剂及治疗方法
RU2018133133A (ru) Способ лечения атрофической возрастной макулярной дегенерации
JP2007535552A5 (enExample)
WO2003070219A1 (en) Drug delivery system for the subconjunctival administration of fine grains
JP2025507154A5 (enExample)
de Smet Corticosteroid intravitreal implants
KR20240156416A (ko) 눈의 병태 치료를 위한 지속적 투여 요법
JP2025508127A5 (enExample)
CN102781452B (zh) 减少与皮质类固醇的眼内使用相关的眼压的发生率的方法
JP2022527276A5 (enExample)
JP2022535223A (ja) 眼疾患治療用組成物
JP2003313119A (ja) 微粒子結膜下投与ドラッグデリバリーシステム
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
US20050192257A1 (en) Predictors for patients at risk for glaucoma from steroid therapy
HK40073855A (en) Bioerodible ocular drug delivery insert and therapeutic method
KALDIRIM et al. Intravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass Syndrome
TW202345804A (zh) 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法
WO2005082374A1 (en) Predictors for patients at risk for glaucoma from steroid therapy
HK1183436A (en) Intraocular pressure reduction with intracameral bimatoprost implants
HK1183436B (en) Intraocular pressure reduction with intracameral bimatoprost implants
NZ732418B2 (en) Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
NZ732418A (en) Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions